PharmaSens and SiBionics Partner to Develop All-in-One Diabetes Patch Pump

PharmaSens AG, a Swiss company specializing in advanced insulin patch pump systems, has forged a strategic partnership with SiBionics, a renowned provider of continuous glucose monitoring technologies. This collaboration aims to develop the niia™ signature, a groundbreaking all-in-one wearable device designed to streamline diabetes management by integrating insulin delivery and glucose sensing into a single, compact patch pump.

This partnership seeks to address the challenges faced by individuals with diabetes who rely on insulin therapy. By combining PharmaSens' expertise in insulin delivery systems with SiBionics' advanced biosensor technology, the joint effort aims to create a device that offers a new level of convenience and user experience. The niia™ signature is intended to significantly reduce the daily complexities and burdens associated with diabetes management.

Marcel Both, CEO of PharmaSens, emphasized the importance of the collaboration, stating, "This partnership marks a significant milestone toward realizing our vision of a fully integrated, discreet, and intuitive insulin-therapy system." SiBionics' well-established proficiency in sensor technology complements PharmaSens' innovative platform, paving the way for the development of this next-generation device.

PharmaSens AG, a privately owned company based in Switzerland, is committed to simplifying diabetes care and expanding access to insulin pump therapy. The company has extensive experience in diabetes management and medical device engineering and has contributed to the development of multiple generations of insulin pumps. Over years of dedicated research and development, PharmaSens has assembled a portfolio of patented international products that are both distinctive and innovative.

SiBionics, founded in 2015, is a leading medical device company with locations in Shenzhen, China, and Irvine, California. The company's core expertise lies in medical device research, development, and innovation. With a team comprising over 500 employees, including a substantial portion of R&D scientists from prestigious universities in China and the U.S., SiBionics is devoted to advancing healthcare technology. Their mission is to enhance patient lives by providing them with deeper health insights through cutting-edge continuous biosensors, intelligent algorithms, and user-friendly software solutions.

The collaboration between PharmaSens and SiBionics represents a promising advancement in diabetes management technology. By leveraging their respective expertise, the two companies are poised to create a wearable device that simplifies the complexities of insulin therapy. The niia™ signature, once developed, will offer patients a more streamlined and less burdensome approach to managing their health.

This innovative partnership highlights the ongoing efforts within the medical device industry to improve the lives of individuals with diabetes. As the development of the niia™ signature progresses, both PharmaSens and SiBionics are committed to delivering a product that not only meets the needs of patients but also sets a new standard for integrated diabetes management solutions.